Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

542 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
Chen GL, Yu XY, Luo LP, Zhang F, Dai XH, Li N, Shen ZW, Wu KQ, Lou DF, Peng CG, Jin TH, Huang YM, Shao X, Liu Q, Jiang Q, Guo T, Cao F, Zhu JR, Wu XH, Pei RJ, Deng F, Jiang GP, Li YH, Gao HN, He JX, Zhong-Chen, Peng YC, Li LJ. Chen GL, et al. Vaccine. 2023 Nov 22;41(48):7297-7306. doi: 10.1016/j.vaccine.2023.10.065. Epub 2023 Nov 3. Vaccine. 2023. PMID: 37925316 Free article. Clinical Trial.
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, Shen J, Ge YH, Shen ZW, Deng YQ, Yang SY, Zhao H, Zhang NN, Zhang YF, Wei L, Wu KQ, Zhu MF, Peng CG, Jiang Q, Cao SC, Li YH, Zhao DH, Wu XH, Ni L, Shen HH, Dong C, Ying B, Sheng GP, Qin CF, Gao HN, Li LJ. Chen GL, et al. Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24. Lancet Microbe. 2022. PMID: 35098177 Free PMC article. Clinical Trial.
Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
Chen GL, Qiu YZ, Wu KQ, Wu Y, Wang YH, Zou YY, Peng CG, Zhao J, Su C, Ma JH, Ni SN, Wang X, Jin TH, Jiang Q, Guo T, Xu Y, Huang CC, Zhang Q, Liu KL, Ji L, Yang HY, Li CL, Su YW, Lu X, Li LJ. Chen GL, et al. Hum Vaccin Immunother. 2023 Dec 15;19(3):2285089. doi: 10.1080/21645515.2023.2285089. Epub 2023 Dec 18. Hum Vaccin Immunother. 2023. PMID: 38111106 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.
Chen GL, Liu Y, Gao XF, Wu KQ, Yang YK, Chen Y, Peng CG, Jin TH, Huang YB, Zhang YW, Su J, Jiang Q, Guo T, Zhao J, Peng XN, Peng JY, Li SX, Sun YL, Zhang HM, Fu YL, Luo D, Ma Y, Shen ZW, Zhang YT, Shou ZF. Chen GL, et al. Among authors: chen y. Diabetes Obes Metab. 2024 Apr;26(4):1395-1406. doi: 10.1111/dom.15441. Epub 2024 Jan 29. Diabetes Obes Metab. 2024. PMID: 38287130 Clinical Trial.
542 results